REGULATORY

Japan to Boost Measures to Ensure COVID Drug Access, Govt Says after Shionogi Antiviral Delay

July 22, 2022
The Japanese government will continue to take all possible measures to strengthen delivery systems for COVID-19 treatments across the country, Chief Cabinet Secretary Hirokazu Matsuno said on June 21, a day after panels of experts delayed a decision on what…

To read the full story

Related Article

REGULATORY

By Sakura Kono

Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…

By Eric Persoff

President Joe Biden enacted the Inflation Reduction Act (IRA) on August 16, 2022, significantly affecting Medicare prescription drug coverage and introducing targeted changes to Medicaid, the Children’s Health Insurance Program, and private health insurance. In January 2023, the Centers for…

By Tatsuya Otsuka

Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…

A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…